RxDoctor Payments Data

Jennifer Writsel, PA

Physician Assistant · Lexington, KYNPI 1730485384

Payments from drug & device makers

$4,776in general payments, 2019–2025

Across 212 payments — averaging $22.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dendreon Pharmaceuticals LLC$514
  • Astellas Pharma US Inc$488
  • Pfizer$440
  • Sumitomo Pharma America, Inc.$398
  • AbbVie$378
  • Johnson & Johnson$283
  • plus $2K from 27 others

What the payments were for

  • Food & beverage$4,67698%
  • Education$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,776 in reported general payments places this provider in the 90th percentile of 1,448 physician assistant providers in Kentucky.

See all physician assistant providers in Kentucky

Medicare billing

Part B allowed, 2024
$142,569
Medicare patients
512
Services billed
3,175

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron113$101,180
MyrbetriqMirabegron95$55,816
Solifenacin Succinate171$11,000
Tamsulosin Hcl416$4,667
Silodosin47$4,314
Estradiol31$2,041
Trimethoprim37$1,951
NitrofurantoinNitrofurantoin Macrocrystal45$1,595
Methenamine Hippurate12$1,592
Cefdinir61$1,168
Cephalexin102$874
Testosterone Cypionate26$694
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst37$547
Doxycycline Hyclate49$512
Finasteride55$491

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$398$101,180113 claims
Astellas Pharma US IncMyrbetriq$488$55,81695 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,448 physician assistant providers in Kentucky.

Other physician assistant in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →